Paper36795409
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer.
Cella CA and 15 others. JAMA Netw Open, 2023. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer. Papers, record 36795409. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36795409
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Venous Thromboembolism | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Female | |
| Middle Aged | |
| Outpatients | |
| Prospective Studies | |
| Risk Assessment |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27882374 | Cancer-associated venous thromboembolism: Burden, mechanisms, and management. | Thromb Haemost | 2017 | https://conductscience.org/library/papers/27882374 | PubMed |
| 2 | 34396323 | Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review. | JACC CardioOncol | 2021 | https://conductscience.org/library/papers/34396323 | PubMed |
| 3 | 20097409 | Venous thromboembolism and prognosis in cancer. | Thromb Res | 2010 | https://conductscience.org/library/papers/20097409 | PubMed |
| 4 | 31492632 | 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31492632 | PubMed |
| 5 | 26114207 | Guideline on aspects of cancer-related venous thrombosis. | Br J Haematol | 2015 | https://conductscience.org/library/papers/26114207 | PubMed |
| 6 | 31353841 | The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. | J Thromb Haemost | 2019 | https://conductscience.org/library/papers/31353841 | PubMed |
| 7 | 24141714 | World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. | JAMA | 2013 | https://conductscience.org/library/papers/24141714 | PubMed |
| 8 | 30919253 | Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. | J Thromb Thrombolysis | 2019 | https://conductscience.org/library/papers/30919253 | PubMed |
| 9 | 29885940 | A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. | Lancet Haematol | 2018 | https://conductscience.org/library/papers/29885940 | PubMed |
| 10 | 28550192 | Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. | Haematologica | 2017 | https://conductscience.org/library/papers/28550192 | PubMed |
| 11 | 22547369 | A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. | Intern Emerg Med | 2012 | https://conductscience.org/library/papers/22547369 | PubMed |
| 12 | 32580190 | Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients. | Oncol Res Treat | 2020 | https://conductscience.org/library/papers/32580190 | PubMed |
| 13 | 19726226 | Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19726226 | PubMed |
| 14 | 20829374 | Prediction of venous thromboembolism in cancer patients. | Blood | 2010 | https://conductscience.org/library/papers/20829374 | PubMed |
| 15 | 21908511 | Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. | Ann Oncol | 2011 | https://conductscience.org/library/papers/21908511 | PubMed |
| 16 | 18216292 | Development and validation of a predictive model for chemotherapy-associated thrombosis. | Blood | 2008 | https://conductscience.org/library/papers/18216292 | PubMed |
| 17 | 31381464 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31381464 | PubMed |
| 18 | 33570602 | American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. | Blood Adv | 2021 | https://conductscience.org/library/papers/33570602 | PubMed |
| 19 | 25987694 | Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25987694 | PubMed |
| 20 | 30511879 | Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30511879 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42555406 | Enhancing venous thromboembolism risk prediction after immunotherapy for lung cancer. | iScience | 2026 | https://conductscience.org/library/papers/42555406 | PubMed |
| 42163826 | Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer. | Clin Appl Thromb Hemost | 2026 | https://conductscience.org/library/papers/42163826 | PubMed |
| 41847697 | Thromboembolic disease in testicular germ cell tumors-real-world evidence of three Portuguese institutions. | Front Oncol | 2026 | https://conductscience.org/library/papers/41847697 | PubMed |
| 41228199 | The Clinical Utility of Selected Coagulation Parameters in Predicting the Risk of Venous Thromboembolism in Neuroendocrine Tumours: A Prospective, Single-Centre Study. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228199 | PubMed |
| 41154365 | Comparative Evaluation of Risk Assessment Models for Predicting Venous Thromboembolic Events in Cancer Patients with Implanted Central Venous Access Devices. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41154365 | PubMed |
| 40325237 | Venous thromboembolic risk in hematological hospitalized patients: a retrospective study. | Ann Hematol | 2025 | https://conductscience.org/library/papers/40325237 | PubMed |
| 40291141 | Development, validation, and clinical utility of risk prediction models for cancer-associated venous thromboembolism: A retrospective and prospective cohort study. | Asia Pac J Oncol Nurs | 2025 | https://conductscience.org/library/papers/40291141 | PubMed |
| 39110395 | SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023). | Clin Transl Oncol | 2024 | https://conductscience.org/library/papers/39110395 | PubMed |
| 38730721 | Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38730721 | PubMed |
| 38625997 | Decision theoretical foundations of clinical practice guidelines: an extension of the ASH thrombophilia guidelines. | Blood Adv | 2024 | https://conductscience.org/library/papers/38625997 | PubMed |
| 38617046 | Venous thromboembolism in pancreatic neuroendocrine neoplasm: a cohort study. | Res Pract Thromb Haemost | 2024 | https://conductscience.org/library/papers/38617046 | PubMed |
| 38275899 | Novel Insights in Venous Thromboembolism Risk Assessment Methods in Ambulatory Cancer Patients: From the Guidelines to Clinical Practice. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38275899 | PubMed |
| 37227679 | Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive. | Intern Emerg Med | 2023 | https://conductscience.org/library/papers/37227679 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SELP | 6403 | PubTator's text mining | https://conductscience.org/library/genes/6403 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36795409
GET https://conductscience.org/api/papers/v1/36795409/references?page=2